Improving long-term outcomes with intensive chemotherapy in AML: looking to the future

Christoph Röllig, MD, MSc, Dresden University of Technology, Dresden, Germany, summarizes an education session delivered at the ASH 2023 meeting, which explored how to improve long-term outcomes with intensive chemotherapy (IC) in patients with acute myeloid leukemia (AML). The 7+3 IC regimen has been used for over 50 years and is the only therapeutic option currently available which leads to long-term remission. Dr Röllig discusses some recent developments, such as the addition of novel agents to the 7+3 regimen, and comments on two possible directions the AML landscape may take regarding IC in the future. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.